Aveo Capital Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Aveo Capital Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,286	Closed	-$272K	–	364
2023 Q4	$272K	Sell	8,286 -7,750	-48%	-$211K	0.03%	283
2023 Q3	$447K	Hold	16,036	–	–	0.06%	211
2023 Q2	$547K	Hold	16,036	–	–	0.07%	192
2023 Q1	$482K	Sell	16,036 -100	-0.6%	-$3.1K	0.06%	198
2022 Q4	$456K	Buy	16,136 +141	+0.9%	+$4.47K	0.07%	200
2022 Q3	$526K	Hold	15,995	–	–	0.09%	160
2022 Q2	$504K	Hold	15,995	–	–	0.08%	176
2022 Q1	$735K	Buy	15,995 +11,658	+269%	+$556K	0.13%	134
2021 Q4	$266K	Sell	4,337 -17	-0.4%	-$1.18K	0.05%	240
2021 Q3	$325K	Buy	+4,354	New	+$365K	0.07%	200

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Aveo Capital Partners's ARKG Position: Q1 2024 in Review

Aveo Capital Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2024, closing a stake of 8,286 shares — an estimated $272K sold.

Aveo Capital Partners first reported a position in ARKG in Q3 2021 and held it in 10 quarters. The position peaked at $735K in Q1 2022. 284 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

Aveo Capital Partners reported no remaining ARK Genomic Revolution ETF position as of Q1 2024 after selling out during the quarter.
Aveo Capital Partners sold 8,286 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $272K.
Aveo Capital Partners first reported a position in ARK Genomic Revolution ETF in Q3 2021 and held it in 10 quarters.
Aveo Capital Partners's ARK Genomic Revolution ETF position peaked at $735K in Q1 2022.
284 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on Aveo Capital Partners's 13F filing for Q1 2024, filed 6 May 2024.